Top

Published in:

01-08-2019 | Molecular Imaging | Editor's Page

Challenges and opportunities for nuclear cardiology

Author: Marcelo F. Di Carli, MD

Published in: Journal of Nuclear Cardiology | Issue 4/2019

Excerpt

Over the last decade, we have witnessed an explosive expansion in the armamentarium of imaging technologies capable of providing detailed information about the structure and function of the heart and vasculature resulting in unprecedented improvements to our ability to diagnose disease, improve patient care, and advance biomedical research.1 Cardiovascular imaging approaches are powerful as they are non-invasive, targeted to the specific biology, and highly quantitative. Along with clinical, molecular, and genome-wide association studies, structural and functional quantitative imaging already plays a critical role in phenotyping cardiovascular disease. There is virtually no cardiovascular condition in which imaging does not play a significant role in diagnosis, risk stratification, or management decisions. The role of imaging continues to evolve and now encompasses the entire continuum of biomedical research and clinical practice. …

Di Carli MF, Geva T, Davidoff R. The future of cardiovascular imaging. Circulation 2016;133:2640-61.CrossRefPubMed

Shaw LJ, Blankstein R, Jacobs JE, Leipsic JA, Kwong RY, Taqueti VR, et al. Defining quality in cardiovascular imaging: A scientific statement from the American Heart Association. Circ Cardiovasc Imaging 2017. https://doi.org/10.1161/HCI.0000000000000017.CrossRefPubMedPubMedCentral

Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010;362:2155-65.CrossRefPubMed

Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9.CrossRefPubMed

Benjamin EJ, Virani SS, Callaway CW, Chang AR, Cheng S, Chiuve SE, et al. Heart disease and stroke statistics—2018 update: A report from the American Heart Association. Circulation 2018;137:e67-492.CrossRefPubMed

Roberts WC. Quantitative extent of atherosclerotic plaque in the major epicardial coronary arteries in patients with fatal coronary heart disease, in coronary endarterectomy specimens, in aorta-coronary saphenous venous conduits, and means to prevent the plaques: A review after studying the coronary arteries for 50 years. Am J Cardiol 2018;121:1413-35.CrossRefPubMed

Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:2625-41.CrossRefPubMedPubMedCentral

Williams MC, Adamson PD, Newby DE. Coronary CT angiography and subsequent risk of myocardial infarction. N Engl J Med 2019;380:300.PubMed

Al-Mallah MH, Hachamovitch R, Dorbala S, Di Carli MF. Incremental prognostic value of myocardial perfusion imaging in patients referred to stress single-photon emission computed tomography with renal dysfunction. Circ Cardiovasc Imaging 2009;2:429-36.CrossRefPubMed

10.

Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol 2004;11:171-85.CrossRefPubMed

11.

Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012;126:1858-68.CrossRefPubMedPubMedCentral

12.

Osborne MT, Bajaj NS, Taqueti VR, Gupta A, Bravo PE, Hainer J, et al. Coronary microvascular dysfunction identifies patients at high risk of adverse events across cardiometabolic diseases. J Am Coll Cardiol 2017;70:2835-7.CrossRefPubMedPubMedCentral

13.

Bajaj NS, Osborne MT, Gupta A, Tavakkoli A, Bravo PE, Vita T, et al. Coronary microvascular dysfunction and cardiovascular risk in obese patients. J Am Coll Cardiol 2018;72:707-17.CrossRefPubMedPubMedCentral

14.

Charytan DM, Skali H, Shah NR, Veeranna V, Cheezum MK, Taqueti VR, et al. Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage. Kidney Int 2018;93:501-9.CrossRefPubMed

15.

Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J 2018;39:840-9.CrossRefPubMed

16.

Majmudar MD, Murthy VL, Shah RV, Kolli S, Mousavi N, Foster CR, et al. Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. Eur Heart J Cardiovasc Imaging 2015;16:900-9.CrossRefPubMedPubMedCentral

17.

Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186-93.CrossRefPubMed

18.

Gould KL, Johnson NP, Roby AE, Nguyen T, Kirkeeide R, Haynie M, et al. Regional, artery-specific thresholds of quantitative myocardial perfusion by PET associated with reduced myocardial infarction and death after revascularization in stable coronary artery disease. J Nucl Med 2019;60:410-7.CrossRefPubMedPubMedCentral

19.

Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation 2015;131:19-27.CrossRefPubMed

20.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018;379:22-31.CrossRefPubMed

21.

Maurer MS, Sultan MB, Rapezzi C. Tafamidis for transthyretin amyloid cardiomyopathy. N Engl J Med 2019;380:196-7.CrossRefPubMed

22.

Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.CrossRefPubMed

23.

Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.CrossRefPubMedPubMedCentral

24.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.CrossRefPubMed

25.

Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-23.CrossRefPubMed

26.

Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.CrossRefPubMed

27.

Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis: The task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;36:3075-128.CrossRefPubMed

28.

Pizzi MN, Roque A, Fernandez-Hidalgo N, Cuellar-Calabria H, Ferreira-Gonzalez I, Gonzalez-Alujas MT, et al. Improving the diagnosis of infective endocarditis in prosthetic valves and intracardiac devices with 18F-fluordeoxyglucose positron emission tomography/computed tomography angiography: Initial results at an infective endocarditis referral center. Circulation 2015;132:1113-26.CrossRefPubMed

29.

Slart R. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: Joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging 2018;45:1250-69.CrossRefPubMedPubMedCentral

30.

Jailkhani N, Ingram JR, Rashidian M, Rickelt S, Tian C, Mak H, et al. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci USA 2019. https://doi.org/10.1073/pnas.1817442116.CrossRefPubMedPubMedCentral

31.

Rashidian M, Keliher EJ, Bilate AM, Duarte JN, Wojtkiewicz GR, Jacobsen JT, et al. Noninvasive imaging of immune responses. Proc Natl Acad Sci USA 2015;112:6146-51.CrossRefPubMedPubMedCentral

Title: Challenges and opportunities for nuclear cardiology
Author: Marcelo F. Di Carli, MD
Publication date: 01-08-2019
Publisher: Springer International Publishing
Keywords: Molecular Imaging
Cardiac Amyloidosis
Published in: Journal of Nuclear Cardiology / Issue 4/2019
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-019-01774-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Challenges and opportunities for nuclear cardiology

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2019

Do we need diagnostic strategies enhanced with genetic information for ischemic heart disease?

David E. Kuhl (1929–2017)

Coronary vascular age: An alternate means for predicting stress-induced myocardial ischemia in patients with suspected coronary artery disease

A troubled marriage: When electrical and mechanical dyssynchrony don’t go along

Potential effects of low-dose average CT on cardiac implantable electronic devices

Development of an inflammation imaging tracer, 111In-DOTA-DAPTA, targeting chemokine receptor CCR5 and preliminary evaluation in an ApoE−/− atherosclerosis mouse model